轻度奥米克龙感染者接种疫苗与持续出现 COVID-19 相关症状之间的关系:前瞻性队列研究

IF 2.7 Q3 IMMUNOLOGY Vaccine: X Pub Date : 2024-11-04 DOI:10.1016/j.jvacx.2024.100579
Marciane Maria Rover , Fernando Luis Scolari , Geraldine Trott , Mariana Motta Dias da Silva , Denise de Souza , Rosa da Rosa Minho dos Santos , Raíne Fogliati De Carli Schardosim , Emelyn de Souza Roldão , Gabriel Pozza Estivalete , Gabriela Soares Rech , Duane Mocellin , Jennifer Menna Barreto de Souza , Aline Paula Miozzo , Carolina Rothmann Itaqui , Gabrielle Nunes da Silva , Juliana de Mesquita Neto , Hellen Jordan Martins Freitas , Catherine Vitória Pereira dos Santos , Alanys Santos da Silveira , Carla Moura D’Ávila , Regis Goulart Rosa
{"title":"轻度奥米克龙感染者接种疫苗与持续出现 COVID-19 相关症状之间的关系:前瞻性队列研究","authors":"Marciane Maria Rover ,&nbsp;Fernando Luis Scolari ,&nbsp;Geraldine Trott ,&nbsp;Mariana Motta Dias da Silva ,&nbsp;Denise de Souza ,&nbsp;Rosa da Rosa Minho dos Santos ,&nbsp;Raíne Fogliati De Carli Schardosim ,&nbsp;Emelyn de Souza Roldão ,&nbsp;Gabriel Pozza Estivalete ,&nbsp;Gabriela Soares Rech ,&nbsp;Duane Mocellin ,&nbsp;Jennifer Menna Barreto de Souza ,&nbsp;Aline Paula Miozzo ,&nbsp;Carolina Rothmann Itaqui ,&nbsp;Gabrielle Nunes da Silva ,&nbsp;Juliana de Mesquita Neto ,&nbsp;Hellen Jordan Martins Freitas ,&nbsp;Catherine Vitória Pereira dos Santos ,&nbsp;Alanys Santos da Silveira ,&nbsp;Carla Moura D’Ávila ,&nbsp;Regis Goulart Rosa","doi":"10.1016/j.jvacx.2024.100579","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>While COVID-19 vaccination has been shown to reduce the risk of severe illness, its impact on the occurrence of persistent symptoms in patients with mild Omicron infection remains uncertain. Our objective was to investigate whether COVID-19 vaccination reduces the occurrence of persistent COVID-19-related symptoms 3 months after mild Omicron infection.</div></div><div><h3>Methods</h3><div>Multicenter prospective cohort study was conducted in Brazil between January 2022 and June 2023 when Omicron was predominant. Participants ≥ 18 years seeking outpatient care for symptomatic SARS-CoV-2 infection were enrolled. Complete vaccination included individuals who received the full primary series and any booster dose, while incomplete vaccination included those with incomplete primary series or no vaccination. The primary outcome was any persistent symptoms at 3 months. Secondary outcomes were organ system-specific persistent symptoms and the EQ-5D-3L utility score. All outcomes were assessed by means of structured telephone interviews 3 months after enrollment.</div></div><div><h3>Results</h3><div>1,067 patients were enrolled (median age, 39 years), of which 914 (871 completely vaccinated and 43 unvaccinated or incompletely vaccinated). Among the vaccinated participants the median time since the last vaccine dose was 145 (interquartile range, 106–251) days. A total of 388/1067 (36.9 %) had a prior infection at the time of study entry<em>.</em> The occurrence of overall persistent COVID-19-related symptoms at 3 months was 41.6 % (n = 362) among completely vaccinated and 44.2 % (n = 19) among unvaccinated or incompletely vaccinated patients (adjusted risk ratio [aRR], 0.87; 95 % confidence interval [CI], 0.61–1.23; <em>p</em> = 0.43). Complete vaccination was associated with lower occurrence of mental health symptoms (aRR, 0.44; 95 % CI, 0.24–0.81; <em>p</em> = 0.01). No differences were found in the occurrence of persistent symptoms in other specific domains, nor in EQ-5D-3L utility scores.</div></div><div><h3>Conclusions</h3><div>This study was not able to identify a statistically significant protection of complete COVID-19 vaccination against any overall persistent symptoms at 3 months. Nevertheless, complete vaccination was associated with a lower occurrence of persistent mental health symptoms.</div></div>","PeriodicalId":43021,"journal":{"name":"Vaccine: X","volume":"21 ","pages":"Article 100579"},"PeriodicalIF":2.7000,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Association between vaccination and persistent COVID-19-related symptoms among patients with mild Omicron infection: A prospective cohort study\",\"authors\":\"Marciane Maria Rover ,&nbsp;Fernando Luis Scolari ,&nbsp;Geraldine Trott ,&nbsp;Mariana Motta Dias da Silva ,&nbsp;Denise de Souza ,&nbsp;Rosa da Rosa Minho dos Santos ,&nbsp;Raíne Fogliati De Carli Schardosim ,&nbsp;Emelyn de Souza Roldão ,&nbsp;Gabriel Pozza Estivalete ,&nbsp;Gabriela Soares Rech ,&nbsp;Duane Mocellin ,&nbsp;Jennifer Menna Barreto de Souza ,&nbsp;Aline Paula Miozzo ,&nbsp;Carolina Rothmann Itaqui ,&nbsp;Gabrielle Nunes da Silva ,&nbsp;Juliana de Mesquita Neto ,&nbsp;Hellen Jordan Martins Freitas ,&nbsp;Catherine Vitória Pereira dos Santos ,&nbsp;Alanys Santos da Silveira ,&nbsp;Carla Moura D’Ávila ,&nbsp;Regis Goulart Rosa\",\"doi\":\"10.1016/j.jvacx.2024.100579\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>While COVID-19 vaccination has been shown to reduce the risk of severe illness, its impact on the occurrence of persistent symptoms in patients with mild Omicron infection remains uncertain. Our objective was to investigate whether COVID-19 vaccination reduces the occurrence of persistent COVID-19-related symptoms 3 months after mild Omicron infection.</div></div><div><h3>Methods</h3><div>Multicenter prospective cohort study was conducted in Brazil between January 2022 and June 2023 when Omicron was predominant. Participants ≥ 18 years seeking outpatient care for symptomatic SARS-CoV-2 infection were enrolled. Complete vaccination included individuals who received the full primary series and any booster dose, while incomplete vaccination included those with incomplete primary series or no vaccination. The primary outcome was any persistent symptoms at 3 months. Secondary outcomes were organ system-specific persistent symptoms and the EQ-5D-3L utility score. All outcomes were assessed by means of structured telephone interviews 3 months after enrollment.</div></div><div><h3>Results</h3><div>1,067 patients were enrolled (median age, 39 years), of which 914 (871 completely vaccinated and 43 unvaccinated or incompletely vaccinated). Among the vaccinated participants the median time since the last vaccine dose was 145 (interquartile range, 106–251) days. A total of 388/1067 (36.9 %) had a prior infection at the time of study entry<em>.</em> The occurrence of overall persistent COVID-19-related symptoms at 3 months was 41.6 % (n = 362) among completely vaccinated and 44.2 % (n = 19) among unvaccinated or incompletely vaccinated patients (adjusted risk ratio [aRR], 0.87; 95 % confidence interval [CI], 0.61–1.23; <em>p</em> = 0.43). Complete vaccination was associated with lower occurrence of mental health symptoms (aRR, 0.44; 95 % CI, 0.24–0.81; <em>p</em> = 0.01). No differences were found in the occurrence of persistent symptoms in other specific domains, nor in EQ-5D-3L utility scores.</div></div><div><h3>Conclusions</h3><div>This study was not able to identify a statistically significant protection of complete COVID-19 vaccination against any overall persistent symptoms at 3 months. Nevertheless, complete vaccination was associated with a lower occurrence of persistent mental health symptoms.</div></div>\",\"PeriodicalId\":43021,\"journal\":{\"name\":\"Vaccine: X\",\"volume\":\"21 \",\"pages\":\"Article 100579\"},\"PeriodicalIF\":2.7000,\"publicationDate\":\"2024-11-04\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Vaccine: X\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2590136224001529\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"IMMUNOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Vaccine: X","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2590136224001529","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

背景虽然COVID-19疫苗接种已被证明可降低重症风险,但其对轻度奥米克龙感染患者持续症状发生的影响仍不确定。我们的目的是研究接种 COVID-19 疫苗是否会减少轻度奥米克隆感染 3 个月后出现的 COVID-19 相关持续症状。方法在 2022 年 1 月至 2023 年 6 月奥米克隆流行期间,在巴西开展了一项多中心前瞻性队列研究。因无症状感染 SARS-CoV-2 而寻求门诊治疗的年龄≥ 18 岁的参与者均被纳入研究范围。完全接种包括接种了完整的初级疫苗系列和任何加强剂量,而不完全接种包括接种了不完整的初级疫苗系列或未接种疫苗。主要结果是 3 个月后出现任何持续症状。次要结果是器官系统特异性持续症状和 EQ-5D-3L 实用性评分。所有结果均通过入组 3 个月后的结构化电话访谈进行评估。结果 1,067 名患者入组(中位年龄 39 岁),其中 914 人(871 人完全接种疫苗,43 人未接种疫苗或未完全接种疫苗)。在已接种疫苗的参与者中,距最后一次接种疫苗的时间中位数为 145 天(四分位距为 106-251 天)。共有 388 人/1067 人(36.9%)在加入研究时曾受到感染。完全接种疫苗的患者在3个月后出现COVID-19相关症状的总体比例为41.6%(n = 362),未接种疫苗或未完全接种疫苗的患者为44.2%(n = 19)(调整风险比[aRR],0.87;95%置信区间[CI],0.61-1.23;p = 0.43)。完全接种与精神健康症状发生率较低有关(调整风险比为 0.44;95 % 置信区间为 0.24-0.81;P = 0.01)。在其他特定领域的持续症状发生率和 EQ-5D-3L 实用性评分方面均未发现差异。不过,完全接种疫苗与较低的持续性精神健康症状发生率有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
Association between vaccination and persistent COVID-19-related symptoms among patients with mild Omicron infection: A prospective cohort study

Background

While COVID-19 vaccination has been shown to reduce the risk of severe illness, its impact on the occurrence of persistent symptoms in patients with mild Omicron infection remains uncertain. Our objective was to investigate whether COVID-19 vaccination reduces the occurrence of persistent COVID-19-related symptoms 3 months after mild Omicron infection.

Methods

Multicenter prospective cohort study was conducted in Brazil between January 2022 and June 2023 when Omicron was predominant. Participants ≥ 18 years seeking outpatient care for symptomatic SARS-CoV-2 infection were enrolled. Complete vaccination included individuals who received the full primary series and any booster dose, while incomplete vaccination included those with incomplete primary series or no vaccination. The primary outcome was any persistent symptoms at 3 months. Secondary outcomes were organ system-specific persistent symptoms and the EQ-5D-3L utility score. All outcomes were assessed by means of structured telephone interviews 3 months after enrollment.

Results

1,067 patients were enrolled (median age, 39 years), of which 914 (871 completely vaccinated and 43 unvaccinated or incompletely vaccinated). Among the vaccinated participants the median time since the last vaccine dose was 145 (interquartile range, 106–251) days. A total of 388/1067 (36.9 %) had a prior infection at the time of study entry. The occurrence of overall persistent COVID-19-related symptoms at 3 months was 41.6 % (n = 362) among completely vaccinated and 44.2 % (n = 19) among unvaccinated or incompletely vaccinated patients (adjusted risk ratio [aRR], 0.87; 95 % confidence interval [CI], 0.61–1.23; p = 0.43). Complete vaccination was associated with lower occurrence of mental health symptoms (aRR, 0.44; 95 % CI, 0.24–0.81; p = 0.01). No differences were found in the occurrence of persistent symptoms in other specific domains, nor in EQ-5D-3L utility scores.

Conclusions

This study was not able to identify a statistically significant protection of complete COVID-19 vaccination against any overall persistent symptoms at 3 months. Nevertheless, complete vaccination was associated with a lower occurrence of persistent mental health symptoms.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Vaccine: X
Vaccine: X Multiple-
CiteScore
2.80
自引率
2.60%
发文量
102
审稿时长
13 weeks
期刊最新文献
Immunogenicities of vaccines including the immunoglobulin M-degrading enzyme of Streptococcus suis, rIdeSsuis, and protective efficacy against serotype 14 in piglets The importance of quality of health campaign information for outcome evaluation. A case study from Guinea-Bissau and Bangladesh Mumps outbreak in Zimbabwe: The case for universal MMR vaccination in Africa The clinical and economic value of enhanced influenza vaccines for the elderly in Argentina Cost of the typhoid conjugate vaccine introduction through an integrated campaign and follow-on routine immunization in Malawi
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1